To Sharpen Focus on the Global Commercialization of Strategic Products and the External Partnership Model, LEO Pharma Makes Changes to Leadership

NOT INTENDED FOR UK MEDIA

At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future.

In light of this, we are announcing the following changes to our Executive Management team:

We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025.

Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania).

Lisa Elliott, currently Vice President, Global Assets and Payer Strategy at LEO Pharma, is promoted to interim head of Global Product Strategy. A search for the head of the new Global Product Strategy function is underway.

EVP, Development, Kreesten Meldgaard Madsen, will be leaving LEO Pharma. While a search has been initiated to find the right candidate to lead the Development organization in the future, a strong interim solution is ready.

Mark Levick – who is currently a member of LEO Pharma’s Board of Directors and Chair of LEO Pharma’s Innovation Committee – will step in as interim EVP of Development. Mark is a Doctor of Medicine and has a PhD in Vaccine Development. His long international career in health care and the pharmaceutical industry spans multiple R&D, clinical and drug development roles, including a role as Global Head of Development for Novartis. Mark’s appointment is effective immediately. Kreesten will support Mark’s transition into the role and will leave LEO Pharma by the end of June 2025.

Finally, a new HR executive has been appointed and will join our Global Leadership Team as EVP, Head of Global People and Corporate Affairs on July 1. The name will be revealed at a later stage in alignment with the current employer. The interim EVP of GPCA, Michael Meyer, steps down.

“We are now at a point on our journey that requires that we start looking towards the longer term, and the profiles needed to shape our future. We need to sharpen our commercial setup and strengthen our development organization to reach our ambitious goals. Adding new profiles to the organization is critical to our aim of realizing the full potential of our strategic product portfolio by launching it globally and expanding its indications,” explains CEO, Christophe Bourdon.

“I’d like to take this opportunity to thank Becki and Kreesten, who have done a tremendous job in leading through the significant restructuring of LEO Pharma during the past couple of years,” adds Christophe.

With these changes, the Global Leadership Team will have the following members:

• Christophe Bourdon, CEO
• Philip Eickhoff, CFO
• Lisa Elliott, VP, Global Product Strategy (interim)
• Anne Jensen, VP, Strategy
• Frederik Kier, EVP, International Operations
• Mark Levick, CDO, Development (interim)
• Jean Monin, EVP, Thrombosis
• Kristian Sibilitz, EVP, Technical Development and Supply
• Robert Spurr, EVP, Region North America
• Jacob Pontoppidan Thyssen, EVP, Science, Search and Innovation
• To be disclosed, EVP, Global People & Corporate Affairs

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by the majority shareholder the LEO Foundation and, from 2021, Nordic Capital. For more information, visit www.leo-pharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250513932792/en/